Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Novartis wet AMD candidate brolucizumab matches Eylea in late-stage studies with 12-week dosing; shares ahead 1%

Published 06/20/2017, 11:14 AM
Updated 06/20/2017, 11:14 AM
© Reuters.  Novartis wet AMD candidate brolucizumab matches Eylea in late-stage studies with 12-week dosing; shares ahead 1%

© Reuters. Novartis wet AMD candidate brolucizumab matches Eylea in late-stage studies with 12-week dosing; shares ahead 1%

  • Results from two Phase 3 clinical trials, HAWK and HARRIER, assessing Novartis' (NVS +0.8%) brolucizumab (RTH258) for the treatment of neovascular age-related macular degeneration (wet AMD) showed it to be non-inferior to Regeneron Pharmaceuticals (REGN +6.9%) and Bayer (DE:BAYGN)'s (OTCPK:BAYRY -1.3%) EYLEA (aflibercept).
  • Brolucizumab, a humanized single-chain antibody fragment with high affinity for all VEGF-A isoforms, showed efficacy over 48 weeks based on one injection every 12 weeks. EYLEA is administered every eight weeks (after a loading phase for both therapies).
  • The data analysis is ongoing and will be be submitted for presentation at an upcoming medical conference. The company plans to submit marketing applications in 2018 after completing the pharmacokinetic study with the final manufacturing process.
  • Now read: Monsanto (NYSE:MON): Majority Of Polled Americans Oppose Bayer Acquisition (Will It Matter?)


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.